Citi on Intellia Therapeutics (NTLA): 'we believe that NTLA-2001 might find its home as a niche offering'
February 23, 2024 9:25 AM
Citi analyst David Lebowitz reiterated a Neutral rating and $31.00 price target on Intellia Therapeutics (NASDAQ: NTLA).The analyst comments "Following ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
